Macquarie Group’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.2K | Buy |
+32
| New | +$16.4K | ﹤0.01% | 900 |
|
|
2025
Q4 | – | Sell |
-13,493
| Closed | -$6.19M | – | 1231 |
|
|
2025
Q3 | $6.19M | Sell |
13,493
-6,150
| -31% | -$2.29M | 0.01% | 913 |
|
|
2025
Q2 | $5.95M | Buy |
19,643
+4,643
| +31% | +$1.38M | 0.01% | 947 |
|
|
2025
Q1 | $4.97M | Hold |
15,000
| – | – | 0.01% | 982 |
|
|
2024
Q4 | $4.63M | Hold |
15,000
| – | – | 0.01% | 962 |
|
|
2024
Q3 | $3.18M | Sell |
15,000
-13,500
| -47% | -$3.45M | ﹤0.01% | 1085 |
|
|
2024
Q2 | $7.99M | Sell |
28,500
-30,457
| -52% | -$7.25M | 0.01% | 857 |
|
|
2024
Q1 | $15.7M | Buy |
58,957
+30,457
| +107% | +$7.18M | 0.02% | 718 |
|
|
2023
Q4 | $6.59M | Hold |
28,500
| – | – | 0.01% | 908 |
|
|
2023
Q3 | $4.16M | Hold |
28,500
| – | – | 0.01% | 975 |
|
|
2023
Q2 | $6.58M | Hold |
28,500
| – | – | 0.01% | 874 |
|
|
2023
Q1 | $6.9M | Hold |
28,500
| – | – | 0.01% | 877 |
|
|
2022
Q4 | $8.27M | Sell |
28,500
-849
| -3% | -$83K | 0.01% | 874 |
|
|
2022
Q3 | $1.92M | Sell |
29,349
-145
| -0.5% | -$10.1K | ﹤0.01% | 1246 |
|
|
2022
Q2 | $2.11M | Hold |
29,494
| – | – | ﹤0.01% | 1278 |
|
|
2022
Q1 | $2.89M | Hold |
29,494
| – | – | ﹤0.01% | 1270 |
|
|
2021
Q4 | $2.5M | Hold |
29,494
| – | – | ﹤0.01% | 1308 |
|
|
2021
Q3 | $2.35M | Buy |
29,494
+743
| +3% | +$64.2K | ﹤0.01% | 1335 |
|
|
2021
Q2 | $2.8M | Hold |
28,751
| – | – | ﹤0.01% | 1313 |
|
|
2021
Q1 | $3.36M | Sell |
28,751
-69
| -0.2% | -$8.04K | ﹤0.01% | 1020 |
|
|
2020
Q4 | $3.2M | Hold |
28,820
| – | – | ﹤0.01% | 975 |
|
|
2020
Q3 | $3.42M | Hold |
28,820
| – | – | 0.01% | 909 |
|
|
2020
Q2 | $3.26M | Buy |
28,820
+320
| +1% | +$31.5K | 0.01% | 887 |
|
|
2020
Q1 | $1.9M | Hold |
28,500
| – | – | ﹤0.01% | 923 |
|
|
2019
Q4 | $2.6M | Hold |
28,500
| – | – | ﹤0.01% | 963 |
|
|
2019
Q3 | $2.46M | Hold |
28,500
| – | – | ﹤0.01% | 971 |
|
|
2019
Q2 | $2.99M | Sell |
28,500
-12,100
| -30% | -$1.3M | 0.01% | 911 |
|
|
2019
Q1 | $5.09M | Buy |
40,600
+1,500
| +4% | +$186K | 0.01% | 780 |
|
|
2018
Q4 | $4.41M | Buy |
39,100
+6,400
| +20% | +$990K | 0.01% | 774 |
|
|
2018
Q3 | $7M | Buy |
32,700
+8,900
| +37% | +$2.23M | 0.01% | 714 |
|
|
2018
Q2 | $6.66M | Buy |
+23,800
| New | +$4.18M | 0.01% | 715 |
|
Other funds holding MDGL
BBA
RI
JT
ACA
PC
Macquarie Group's MDGL Position: Q2 2026 in Review
Macquarie Group opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 32 shares worth $17.2K. The stake represents ﹤0.01% of the portfolio and ranks #900 among its holdings. This is a return to the name: Macquarie Group previously reported a position in MDGL as recently as Q3 2025.
Macquarie Group first reported a position in MDGL in Q2 2018 and has held it in 31 quarters since. The position peaked at $15.7M in Q1 2024. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.
- Macquarie Group held 32 shares of Madrigal Pharmaceuticals worth $17.2K as of Q2 2026.
- Madrigal Pharmaceuticals was a new Macquarie Group position in Q2 2026.
- Madrigal Pharmaceuticals made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #900 holding.
- Macquarie Group first reported a position in Madrigal Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
- Macquarie Group's Madrigal Pharmaceuticals position peaked at $15.7M in Q1 2024.
- 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.
Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.